![Ian Keith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ian Keith
Direttore/Membro del Consiglio presso MAP Patient Access Ltd.
Profilo
Ian Keith has a current job as a Director at MAP Patient Access Ltd.
Posizioni attive di Ian Keith
Società | Posizione | Inizio |
---|---|---|
MAP Patient Access Ltd.
![]() MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022. | Direttore/Membro del Consiglio | 01/02/2020 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
MAP Patient Access Ltd.
![]() MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022. | Commercial Services |
- Borsa valori
- Insiders
- Ian Keith